Randy Osborne

4 weeks ago | bioworld.com | Randy Osborne

Home » Split ends itepekimab in COPD? Regeneron phase III setup hairy BioWorld briefs for May 30, 2025. BioWorld MedTech briefs for May 29, 2025. BioWorld Asia briefs for May 27, 2025 Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific... STAT6 plays a central role in regulating Th2-driven immune responses.

4 weeks ago | bioworld.com | Randy Osborne

Nex-z phase III enzyme dime-drop chops Intellia in ATTR-CM Investors found in an 8-K filing by Intellia Therapeutics Inc. the news of one case of liver-enzyme elevation in the ongoing phase III Magnitude study with nexiguran ziclumeran (nex-z, NTLA-2001), and in reaction pushed shares of the firm (NASDAQ:NTLA) down to close May 29 at $7.45, a loss of $2.21, or 23%, after the stock traded as low as $6.90 during the day. BioWorld Cardiovascular Gene therapy U.S.

1 month ago | bioworld.com | Randy Osborne

PG rating: Inflarx review declares phase III bombBackers of Jena, Germany-based Inflarx NV have turned their attention to the rest of the pipeline after the stock-jolting news from an independent data monitoring committee (DMC) responsible for the unblinded interim analysis of the phase III trial with vilobelimab in pyoderma gangrenosum (PG).

1 month ago | bioworld.com | Randy Osborne

Home » Houston, a problem: Rocket death in Danon stalls phase II programHouston, a problem: Rocket death in Danon stalls phase II programRocket Pharmaceuticals Inc. CEO Gaurav Shah said his firm is investigating how its gene therapy for Danon disease may have created an “unexpected and paradoxical” effect that led to problems for a phase II patient who ultimately died. BioWorld Clinical Cardiovascular Endocrine/metabolic Gene therapy U.S. FDA

1 month ago | bioworld.com | Randy Osborne

Merus combo trounces Keytruda in head-and-neck phase IIInvestor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results impressed Wall Street in head and neck squamous cell carcinoma. Shares of Utrecht, the Netherlands-based Merus (NASDAQ:MRUS) jumped, too, closing May 23 at $55.14, up $13.54, or 33%, on interim data as of the Feb. 27 cutoff date.